These results indicate that the KRAS mutant promotes chemoresistance in lung cancer cells, a phenomenon correlated with the upregulation of ERK/JNK signaling as well as increased ALKBH5 phosphorylation and SUMOylation. The gene discussed is KRAS; the disease is lung carcinoma.